Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. Patient biomarker status (e.g., BRAF, RAS, MSI-H/dMMR) and tumor location play a key role in guiding treatment selection. Immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo and Yervoy) and BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi) have recently emerged as novel options and will see robust uptake in eligible patients. Further personalization of treatment will ensure continued uptake of currently approved therapies over the 2020-2030 forecast period. We also expect several novel agents and combinations to impact the market and help address the high unmet need for additional and more-efficacious treatments.
QUESTIONS ANSWERED
How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?
What are key opinion leaders’ views on current and emerging therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?
Which pipeline products are poised to launch for colorectal cancer, and what unmet needs do they address?
What are the key drivers and constraints on the colorectal cancer therapy market, and how will the major markets evolve over the 10-year forecast period?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.